key: cord-0980256-hcdr0eab
authors: Brooker, Helen; Williams, Gareth; Hampshire, Adam; Corbett, Anne; Aarsland, Dag; Cummings, Jeffrey; Molinuevo, Jose Luis; Atri, Alireza; Ismail, Zahinoor; Creese, Byron; Fladby, Tormod; Thim‐Hansen, Charlotte; Wesnes, Keith; Ballard, Clive
title: FLAME: A computerized neuropsychological composite for trials in early dementia
date: 2020-10-14
journal: Alzheimers Dement (Amst)
DOI: 10.1002/dad2.12098
sha: f2a6af8fc5d6ee6ddb436340e2d1410fcd5be30e
doc_id: 980256
cord_uid: hcdr0eab

INTRODUCTION: Sensitive neuropsychological tests are needed to improve power for clinical trials in early Alzheimer's disease (AD). METHODS: To develop a neuropsychological composite (FLAME – Factors of Longitudinal Attention, Memory and Executive Function), we assessed, 10,714 participants over the age of 50 from PROTECT with validated computerized assessments for 2 years. A factorial analysis was completed to identify the key cognitive factors in all participants, and further analyses examined sensitivity to change in people with stage 2/3 early Alzheimer's disease (AD) according to the US Food and Drug Administration (FDA) framework. RESULTS: The FLAME composite score (speed of attention, accuracy of attention, memory, and executive function) distinguished between normal cognition and stage 2/3 early AD at baseline, and was sensitive to cognitive and global/functional decline over 2 years, with the potential to improve power for clinical trials. DISCUSSION: FLAME is sensitive to change, providing a straightforward approach to reduce sample size for RCTs in early AD. CONCLUSION: FLAME is a useful computerized neuropsychology composite with utility for clinical trials focusing on cognition.

There are currently more than 40 million people worldwide living with Alzheimer's disease (AD) and other dementias, increasing to more than 100 million by 2050. 1 In addition, it is estimated that at least 15% of people age 60 or above have mild cognitive impairment (MCI) , and that between 8% and 15% of these will progress to dementia each year, most commonly to AD. 2 In the last 20 for neuropsychological test sensitivity better than conventional pen and paper testing. With computerized assessments, test presentation is more consistent, problems with inter-rater reliability are avoided, and millisecond reaction times can be easily captured. In addition, many of the tests are free of learning effects, thereby enabling repeat testing to reduce variability. [12] [13] [14] [15] Test batteries such as the Cognitive Drug

Research battery and CogTrack, have already been shown to be sensitive to change in trials of cholinesterase inhibitors, 16 other trials of symptomatic drugs, 17 evaluation of natural products, 18 ings showed that at baseline the sub-group of participants with selfreported MCI/AD diagnoses from the 6463 subjects age 55 and older had a poorer performance on the online CBB tests. 28 A composite score from COGSTATE has also been evaluated cross-sectionally in more than 4000 people from the A4 study of people with presymptomatic familial AD, showing significant but surprisingly modest differences between people who were amyloid positive and amyloid negative and modest correlations with the PACC paper and pencil composite. 29 Longitudinal data have been collected for cognitively normal individuals for each of these platforms, 23, 26, 30 but learning effects have been reported with both COGSTATE and CANTAB, 30, 31 which could impact sensitivity to change longitudinally. There are a couple of modest longitudinal studies with CANTAB that present longitudinal data for 18 months or longer in people with early cognitive impairment. The largest of these used CANTAB to assess a cohort including 59 people with MCI followed for 18 to 24 months as part of a study focusing on subjective cognitive decline. A number of different evaluation models were presented, highlighting significantly greater decline in people with MCI than those with subjective cognitive decline in the absence of MCI. 32 Although there are therefore some encouraging data, the potential for practice effects with some of the test batteries is a concern, and larger longitudinal studies in people with MCI and/or early AD are needed to determine sensitivity to change in these individuals across core cognitive domains. The key question of whether computerized neuropsychological assessments could provide a more sensitive approach to the development of a clinical trial neuropsychology composite for people with early AD or MCI requires more evidence from larger longitudinal studies that include at-risk populations and assess core aspects of cognitive function. 24 The current study examines 2 years of cognitive data derived from detailed computerized neuropsychological evaluation of more than 10,000 people over the age of 50, including 1699 with a level of cognitive impairment consistent with stage 2 or stage 3 early AD, to optimize a neuropsychological composite that is sensitive to change. 

All participants completed a series of online self-report questionnaires

annually. This included demographic information (date of birth, gender, highest level of education) and a self-rated assessment of global 

The FDA guidelines describe stage 2 and stage 3 early AD as predementia stages of the disease. 11 Stage 2 in the FDA guideline describes individuals with neuropsychological impairments on sensitive testing in the absence of functional impairments. The FDA paper TA B L E 1 Neuropsychological test descriptions and outcome measures contributing to composites

PROTECT Core Neuropsychological Tests Self-ordered search Total score (Memory) 5 Minutes Average b A series of boxes are present on the screen; one of the boxes will contain a diamond. The volunteer selects each box until they locate the diamond. The diamond is then placed in another box and again the volunteer must locate it, but they must be careful not to select the box in which the diamond was previously found. Higher scores are achieved through efficient location of the diamond. This task measures working memory.

Total score (Memory) 3 Minutes Average b A series of objects appear in the cells on screen. The volunteer is instructed to remember the cell in which the object appears. When an object appears at the bottom center, the volunteer is instructed to click on the cell in which they recall seeing that object. The volunteer is given three attempts at each level. This task measures working memory and learning.

Total score (Memory) 3 Minutes Average b Using a ratchet-style approach in which each successful trial is followed by a new sequence that is one digit longer than the last and each unsuccessful trial is followed by a new sequence that is one digit shorter than the last. This task measures aspects of attention.

Total Score (executive function) Median Speed of correct responses (executive function) Standard Deviation of correct responses (executive function) Accuracy (executive function)

A sentence is displayed at the bottom of the screen whilst a square and a circle are displayed above. The volunteer needs to respond as to whether the sentence correctly or incorrectly describes the configuration of the circle and square. The task measures verbal/grammatical reasoning. The two possible stimuli in this task that can appear on screen. Equal amounts of each stimuli type will be displayed. The volunteer is required to respond with the correct response key as quickly as possible every time the stimuli appears on screen. The accuracy and speed of each is response is recorded. The volunteer is required to respond as quickly as possible when a stimulus is presented in the center of the screen. The volunteer is informed that the stimuli will be presented one at a time and that they will remain there until a response is made. The speed of each response is recorded. a This is the time for a single session administration of the test. b Timings wise this task is performance driven so can be as short as 1.5 minutes. c A verbal reasoning task was part of both the PROTECT and CogTrack battery with different presentations and outcome measures. The CogTrack version did not restrict time for volunteers.

does not highlight specific tests or thresholds, but implies that it is a sensitive level of impairment across more than one cognitive domain.

In the current study, stage 2 was operationalized to include participants who scored >1 SD below benchmarked norms 15,43-45 on at least two of the four PROTECT neuropsychological tests of memory and executive function (Table 1) . Stage 3, requiring people to have neuropsychological and subtle functional impairments, was operationalized to include participants who scored >1.5 SD below benchmarked norms 15,43 on at least two of the four PROTECT tests and had a total IQCODE score ≥64. 34 The FDA paper also discusses clinically meaningful outcomes 

A principal components analysis (or PCA) together with Varimax rotation was done to identify the factor structure within the neuropsychological tests undertaken using the average baseline data from all participants. Factors with eigenvalues greater than unity and factor loadings of 0.4 and above were considered to indicate that a specific task mapped to an identified factor. The derived composites were then applied to examine longitudinal decline in people with early AD (stage 2, stage 3) as a validation cohort (described in the section below).

All analyses of longitudinal data were conducted using the R statistical 

Detailed computerized neuropsychological assessments were available for 10,714 participants at baseline, of whom complete 2-year follow-up data were available for 8965 individuals (84%). A total of 1078 people with complete follow-up data met the study criteria for stage 2 early AD at baseline, and 621 individuals met study criteria for stage 3 early AD at baseline.

The cohort characteristics are described in Table 2 .

Seventy-three percent of participants were female, the mean age was 61.7 (SD 7.13), and 29% of the cohort reported a family history of dementia. The PCA identified four factors: speed of attention (factor 1), accuracy of attention (factor 2), memory (factor 3) and executive function (factor 4) ( Table 3) .

Each factor was normalized to a maximum score of 100. The baseline scores for people with normal cognition, stage 2 early AD, and stage 3 early AD are shown in Table 4 . (FLAME: Factors of Longitudinal Attention, Memory and Executive Function).

Participants meeting the criteria for stage 2 early AD and stage 3 early AD showed significantly greater impairment on each of the four cognitive domains compared to people with normal cognition (P < 0.0001 for all cognitive domains). There were also significant differences in global change and function between the groups (early AD 

For the combined FLAME score and for each cognitive factor, a statistically significant decline in performance over 2 years was observed by group (stage 3 early AD >stage 2 early AD >normal cognition) ( Table 5) .

Seventeen percent of people with stage 2 or stage 3 early AD undertook regular brain training; the sensitivity to change was unaltered in a further analyses excluding these individuals. 

Twenty-five percent of the longitudinal change in FLAME score over 2 years was calculated. This enabled an estimated sample size to be calculated for a 25% treatment effect over 2 years independently for stage 2 and stage 3 early AD. For a trial with 80% power and requiring a significance level of 0.05. Using this method, 119 people per treatment arm would be required to achieve this level of power for a trial in people with stage 2 early AD and 132 people per arm for a trial with this level of power in people with stage 3 early AD with the FLAME composite (Table 6) . 

Over 2 years there was a highly significant correlation between decline in neuropsychological performance on the total FLAME composite and IQCODE score as an indicator of decline in function. There was also a significant correlation between decline in each of the four individual cognitive factors in FLAME respectively and worsening function as indicated by IQCODE (Table 9) . 

The current article presents a longitudinal study of 1699 people with neuropsychological impairments consistent with stage 2 or stage 3 early AD as part of a study of 10,000 people over the age of 50 from PROTECT. The FLAME composite score covering four domains of cognition, incorporating speed of attention, accuracy of attention, TA B L E 5 Differences in 2-year longitudinal change in the progression of cognitive impairment between early dementia (stage 2) and early dementia (stage 3), respectively, and people with normal cognition The main goal of the current study was to determine whether a computerized neuropsychological measure was more sensitive to change in people with early AD or MCI than previously reported for traditional tests. The neuropsychology composite uses widely used and wellvalidated computerized neuropsychological tests. The specific components of the FLAME composite were developed using baseline data from all participants in the study, including those with normal cognition. The derived composite was then applied to examine longitudinal decline in people with a level of cognitive impairment compatible with stage 2 and stage 3 early AD, using the 2018 FDA framework, 11 as a validation cohort.

Grill et al. 10 

World Alzheimer Report Alzheimer's Disease International

Mild cognitive impairment

Memantine in moderate-to-severe Alzheimer's disease

Sodium oligomannate: first approval

Randomized trial of verubecestat for prodromal Alzheimer's disease

Trial of solanezumab for mild dementia due to Alzheimer's disease

Promising results from Alzheimer's disease passive immunotherapy support the development of a preventive vaccine

Understanding disease progression and improving Alzheimer's disease clinical trials: recent highlights from the Alzheimer's disease Neuroimaging Initiative

Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative

Repeated cognitive testing reduces sample size necessary to detect clinically relevant effects

Practice effects on cognitive tasks: a major problem?

Practice effects due to serial cognitive assessment: implications for preclinical Alzheimer's disease randomized controlled trials

The effect of an online cognitive training package in healthy older adults: an online randomized controlled trial

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies

The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers

Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease

Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort

The Cognitive-functional composite is sensitive to clinical progression in early dementia: longitudinal findings from the Catch-Cog study cohort

ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials

A comparison of computerized and pencil-and-paper tasks in assessing cognitive function in community-dwelling older people in the Newcastle 85+ Pilot Study

Moving beyond the pros and cons of automating cognitive testing in pathological aging and dementia: the case for equal opportunity

Online study partnerreported cognitive decline in the Brain Health Registry

The Paired Associates Learning (PAL) test: 30 years of CANTAB translational neuroscience from laboratory to bedside in dementia research

Benefits of rivastigmine on attention in dementia associated with Parkinson disease

Unsupervised online neuropsychological test performance for individuals with mild cognitive impairment and dementia: results from the Brain Health Registry

on behalf of the A4 Study Team. The computerized cognitive composite (c3) in a4, an alzheimer's disease secondary prevention trial

Longitudinal comparison of in clinic and at home administration of the cogstate brief battery and demonstrated practice effects in the Mayo Clinic Study of Aging

Evidence of practice effect in CANTAB spatial working memory test in a cohort of patients with mild cognitive impairment

Changes in visual memory in mild cognitive impairment: a longitudinal study with CANTAB

Online assessment of risk factors for dementia and cognitive function in healthy adults

The informant questionnaire on cognitive decline in the elderly (IQCODE): a review

Informant questionnaire on cognitive decline in the elderly (IQCODE) for classifying cognitive dysfunction as cognitively normal, mild cognitive impairment, and dementia

A three-minute reasoning test based on grammatical transformation. Psychometric science

Carotid endarterectomy improves cognitive function in-patients with exhausted cerebrovascular reserve

Potentiation of cognitive effects of Ginkgo biloba by complexation with phosphatidylserine

Early detection of Alzheimer's disease (AD) using the CANTAB paired Associates Learning Test

Planning and spatial working memory following frontal lobe lesions in man

Verbal working memory impairment in schizophrenia patients and their firstdegree relatives: evidence from the digit span task

Utility, reliability, sensitivity and validity of an online test system designed to monitor changes in cognitive function in clinical trials

Putting brain training to the test

Fractionating human intelligence

Distinct patterns of structural damage underlie working memory and reasoning deficits after traumatic brain injury

Statistical Power Analysis for the Behavioral Sciences

Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease

FLAME: A computerized neuropsychological composite for trials in early dementia